Related Experiment Videos
[Anticoagulation in atrial fibrillation: not yet settled]
R Montagna1, R Asenjo, R Madariaga
1Centro Nacional de Arritmias, Hospital Clínico Universidad de Chile, Santiago, Chile.
Revista Medica De Chile
|October 21, 1998
Summary
Atrial fibrillation, a common heart rhythm disorder, poses risks of blood clots and stroke. This review covers anticoagulation strategies for non-rheumatic atrial fibrillation, aiding risk assessment and treatment choices.
Area of Science:
- Cardiology
- Electrophysiology
- Pharmacology
Context:
- Atrial fibrillation is the most prevalent adult arrhythmia.
- Complications, particularly thrombi formation and embolization, are significant concerns.
- Effective anticoagulation is crucial for preventing embolic events in atrial fibrillation.
Purpose:
- To review current anticoagulation practices for non-rheumatic atrial fibrillation.
- To provide tools for assessing embolic risk.
- To guide anticoagulant selection based on atrial fibrillation presentation.
Summary:
- This review synthesizes the current understanding of anticoagulation in atrial fibrillation, excluding cases related to rheumatic valvulopathy.
- It details risk factors for embolic complications and evaluates the efficacy of anticoagulant therapies.
- The work offers practical guidance for risk stratification and personalized anticoagulant selection.
Impact:
- Enhances clinical decision-making for managing atrial fibrillation.
- Aims to reduce the incidence of stroke and systemic embolism in affected patients.
- Provides a valuable resource for healthcare professionals treating atrial fibrillation.